Plan for Long Haul, Analyst Warns
Vital Therapies Files $86M IPO; Cycle ‘Sure To Turn,’ but When?
By Randy Osborne
Monday, October 14, 2013
“Caveat emptor” is a warning hardly needed by seasoned investors in biotech, many of whom understand the failure-fraught industry and are cautious buyers, when they can be persuaded to buy at all.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.